Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of fixed-dose fenofibrate + metformin in type 2 diabetes mellitus with dyslipidemia
2006-002848-28Phase 3Completed
- Sponsor
- Fournier
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenofibrate + metformin in type 2 diabetes mellitus (T2DM) and dyslipidemia, sponsored by Fournier. Primary endpoints: Patient acceptability of fixed-dose fenofibrate + metformin at baseline (V1) and Patient acceptability of fixed-dose fenofibrate + metformin after 4 weeks (V2). Started Aug 2006; status: completed.
02
Drugs
fenofibrate + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on 2006-002848-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002848-28.